The ARG1 Knockout DLD-1 Polyclonal Cells product comprises a polyclonal population of DLD-1 human colorectal adenocarcinoma cells genetically modified via CRISPR/Cas9-mediated disruption of the endogenous ARG1 gene. This heterogeneous knockout model bypasses clonal expansion and single-cell bottlenecks, thereby preserving the inherent complexity, genomic heterogeneity, and adaptive responses to gene loss across the entire cell population. The polyclonal format provides a robust, reproducible loss-of-function system suitable for high-throughput screening, pooled functional genomics, and assays where population-level metabolic or immune-modulatory phenotypes are interrogated without the confounding influence of clonal artifacts.
The parental DLD-1 cell line is a well-characterized model of colorectal adenocarcinoma isolated from a male patient. It carries key driver mutations commonly found in colorectal cancer, including a nonsense mutation in the adenomatous polyposis coli (APC) tumor suppressor gene, an activating G13D mutation in KRAS, and a missense mutation (S241F) in TP53. These genetic lesions disrupt Wnt signaling, sustain proliferative RAS/MAPK pathway activity, and impair p53-mediated DNA damage responses, collectively recapitulating the aggressive, genomically unstable phenotype of human colorectal tumors. DLD-1 cells grow as adherent epithelial monolayers and are widely employed to study tumor cell-intrinsic signaling, metabolic reprogramming, and the interaction between oncogenotype and the tumor microenvironment.
ARG1 encodes arginase-1, a manganese-dependent enzyme that catalyzes the hydrolysis of L-arginine to L-ornithine and urea, a key step in the urea cycle. In immune cell biology, ARG1 serves as a central metabolic checkpoint: by depleting extracellular L-arginine, it limits substrate availability for inducible nitric oxide synthase (NOS2), thereby reducing nitric oxide production and impairing antigen-driven T-cell proliferation. ARG1 transcription is primarily activated through IL-4 and IL-13 receptor signaling via the JAK/STAT6 pathway, with cooperative involvement of C/EBP??; it is further modulated by TGF-?? and M2 macrophage polarization signals. Downstream, L-ornithine feeds into polyamine synthesis via ornithine decarboxylase (ODC1), producing putrescine and spermidine, which support cell growth and collagen synthesis. Accordingly, ARG1 functionally competes with NOS2 for L-arginine, while its activity intersects with the urea cycle enzymes OTC, ASS1, and ASL. This molecular network positions ARG1 as a pivotal enzyme linking amino acid metabolism to immunosuppressive pathways.
Within the DLD-1 colorectal cancer context, ARG1 is relevant to the growing understanding of how tumor cells reshape the metabolic milieu to evade anti-tumor immunity. Colorectal tumors often exhibit elevated arginase activity, which correlates with suppressed local T-cell function and poor prognosis. The APC, KRAS, and TP53 mutations present in DLD-1 may influence arginine metabolic flux through crosstalk with mTOR signaling, glutamine metabolism, or oxidative stress pathways. By ablating ARG1 in this defined oncogenetic background, researchers can dissect the relative contribution of tumor-intrinsic arginase activity to immune escape, polyamine-dependent proliferation, and the metabolic crosstalk between cancer cells and infiltrating immune cells, independent of macrophage-derived ARG1.
This ARG1 knockout model enables a broad spectrum of mechanistic and translational investigations. It is particularly suited for dissecting how loss of tumor cell arginase-1 alters the local L-arginine pool and modulates T-cell function in co-culture systems, measurable via T-cell suppression assays and flow cytometry-based immune profiling. Combined with arginase activity assays, liquid chromatography-mass spectrometry for arginine/ornithine quantification, and RNA-seq-based metabolic gene expression analysis, the system facilitates quantitative mapping of arginine metabolic rewiring. Additionally, Western blotting and RT-qPCR can monitor compensatory changes in NOS2, ODC1, and other pathway components. For further technical details and experimental support, please contact Ascent Research.
